Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. [electronic resource]
Producer: 20210528Description: 1093-1101 p. digitalISSN:- 1745-7254
- Animals
- Anti-Inflammatory Agents -- therapeutic use
- Cardiomyopathies -- drug therapy
- Diet, High-Fat
- Dose-Response Relationship, Drug
- Fibrosis -- drug therapy
- HEK293 Cells
- Humans
- Inflammation -- drug therapy
- Macrophages, Peritoneal -- drug effects
- Male
- Mice, Inbred C57BL
- Myeloid Differentiation Factor 88 -- antagonists & inhibitors
- Myocardium -- pathology
- NF-kappa B -- metabolism
- Obesity -- complications
- Piperazines -- therapeutic use
- Rats
- Signal Transduction -- drug effects
- Thiazoles -- therapeutic use
- Toll-Like Receptor 4 -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.